Janus Henderson Group PLC Sells 346,533 Shares of Vaxcyte, Inc. (NASDAQ:PCVX)

Janus Henderson Group PLC reduced its holdings in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 3.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 10,575,363 shares of the company's stock after selling 346,533 shares during the quarter. Janus Henderson Group PLC owned 8.48% of Vaxcyte worth $865,605,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. CIBC Asset Management Inc lifted its position in shares of Vaxcyte by 5.5% during the fourth quarter. CIBC Asset Management Inc now owns 3,307 shares of the company's stock valued at $271,000 after purchasing an additional 171 shares in the last quarter. Bridgefront Capital LLC lifted its position in shares of Vaxcyte by 4.2% during the 4th quarter. Bridgefront Capital LLC now owns 4,244 shares of the company's stock worth $347,000 after buying an additional 172 shares in the last quarter. Smartleaf Asset Management LLC boosted its stake in shares of Vaxcyte by 188.4% in the 4th quarter. Smartleaf Asset Management LLC now owns 398 shares of the company's stock worth $33,000 after buying an additional 260 shares during the last quarter. Catalyst Funds Management Pty Ltd boosted its stake in shares of Vaxcyte by 1.7% in the 4th quarter. Catalyst Funds Management Pty Ltd now owns 18,400 shares of the company's stock worth $1,506,000 after buying an additional 300 shares during the last quarter. Finally, Whipplewood Advisors LLC bought a new position in shares of Vaxcyte in the fourth quarter valued at approximately $28,000. Institutional investors and hedge funds own 96.78% of the company's stock.

Insider Buying and Selling

In other news, COO Jim Wassil sold 8,000 shares of the business's stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $73.27, for a total transaction of $586,160.00. Following the completion of the transaction, the chief operating officer now directly owns 154,931 shares in the company, valued at $11,351,794.37. The trade was a 4.91% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 3.10% of the stock is currently owned by insiders.

Vaxcyte Trading Down 2.0%

Shares of NASDAQ PCVX traded down $0.61 during midday trading on Wednesday, hitting $29.44. The company's stock had a trading volume of 165,143 shares, compared to its average volume of 1,316,931. The firm has a market capitalization of $3.80 billion, a price-to-earnings ratio of -6.42 and a beta of 1.27. The stock has a fifty day moving average price of $44.91 and a 200 day moving average price of $73.32. Vaxcyte, Inc. has a one year low of $27.66 and a one year high of $121.06.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last posted its earnings results on Wednesday, May 14th. The company reported ($1.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.02) by ($0.02). During the same period in the previous year, the firm posted ($0.85) earnings per share. On average, equities research analysts predict that Vaxcyte, Inc. will post -4.21 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on PCVX shares. Guggenheim reiterated a "buy" rating and set a $160.00 price target on shares of Vaxcyte in a report on Wednesday, March 12th. Bank of America decreased their target price on Vaxcyte from $157.00 to $137.00 and set a "buy" rating for the company in a research report on Tuesday, April 1st. The Goldman Sachs Group cut their price target on shares of Vaxcyte from $138.00 to $100.00 and set a "buy" rating on the stock in a report on Tuesday, April 1st. Evercore ISI upgraded shares of Vaxcyte to a "strong-buy" rating in a research report on Monday, March 31st. Finally, Cantor Fitzgerald initiated coverage on shares of Vaxcyte in a research report on Tuesday, April 22nd. They issued an "overweight" rating on the stock. Nine research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Vaxcyte has a consensus rating of "Buy" and a consensus target price of $136.50.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.